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OBJECTIVES—To provide a simple clinical diabetes risk score; to identify characteristics 
which predict later diabetes using variables available in clinic, then additionally biological 
variables and polymorphisms.  
RESEARCH DESIGN AND METHODS—Incident diabetes was studied in 1863 men and 
1954 women, 30-65 years at baseline, by treatment or by fasting plasma glucose 
≥ 7.0 mmol/l at 3-yearly examinations over nine years. Sex-specific logistic regression 
equations were used to select variables for prediction. 
RESULTS—140 men, 63 women developed diabetes. The predictive clinical variables 
were: waist circumference and hypertension in both sexes; for men: smoking, for women: 
diabetes in the family. Discrimination, as measured by the areas under the receiver 
operating curves (AROC), were 0.713 for men and 0.827 for women, a little higher than for 
the FINDRISC score, with fewer variables in the score. Combining clinical and biological 
variables, the predictive equation included for men: fasting glucose, waist circumference, 
smoking, γ-glutamyltransferase; for women fasting glucose, BMI, triglycerides, diabetes in 
family. The number of TCF7L2 and IL6 deleterious alleles was predictive in both sexes, 
but after including the above clinical and biological variables, this variable was only 
predictive in women (p < 0.03) and the AROC statistics increased only marginally.  
CONCLUSIONS—The best clinical predictor of diabetes is adiposity, and baseline glucose 
is the best biological predictor. Clinical and biological predictors differed marginally 
between men and women. The genetic polymorphisms added little to the prediction of 
diabetes.  
 
Key words: epidemiology, diabetes, incidence 
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A number of diabetes risk scores have been developed to detect those who should be 
screened for diabetes (1). In the Data from an Epidemiological Study on the Insulin 
Resistance Syndrome (D.E.S.I.R.) cohort we have already studied the anthropometric 
variables associated with diabetic levels of fasting glucose and found that BMI, waist 
circumference and waist-hip ratio were equally useful in their identification of individuals 
with undiagnosed diabetes (2).  
 The first score to identify lifestyle and clinical parameters predictive of later diabetes 
was developed by Lindström and Tuomilehto (3), from a population-based sample of 
people who responded to questionnaires in 1987; 10-year incident diabetes was identified 
from a registry of diabetes treatment. A similar Finnish Diabetes Risk Score, FINDRISC, 
was used in a cross sectional study (4). In the American ARIC study, and in a Thai 
population, predictive risk factors were also identified, diabetes was defined by treatment 
or diabetic levels of fasting and 2 hr glucose from an oral glucose tolerance test 
(OGTT)(5,6). More recently Simmons published a score from the EPIC-Norfolk study, with 
incident diabetes defined by clinical identification of diabetes or an HbA1c > 7% (7), which 
included dietary factors and physical activity. Finally, dietary and other non-invasive factors 
associated with 5-year incident, self-reported cases of diabetes, were identified in the large 
EPIC-Potsdam study (8).  
 In the San Antonio Study, Stern published a score based on prospective clinical and 
biological data (9). In the Framingham cohort, four scores were proposed, a clinical score 
and three scores with both clinical and biological factors with incident diabetes identified at 
follow up by diabetic treatment and/or fasting glucose levels (10).  
 Other studies on diabetes risk factors include one in French men with impaired 
fasting glucose (6.1-6.9 mmol/l), which identified lifestyle, clinical and biological factors 
predictive of diabetes (11).  
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 As risk scores cannot always be generalized from one country to another (12,13), 
the aim of this study was to describe sex-specific lifestyle and clinical diabetes risk factors 
in a French population followed over 9 years, which would aid in identifying those at risk 
for incident diabetes. The additional aims were to study the impact of biological factors and 
genetic polymorphisms in predicting diabetes. 
 
RESEARCH DESIGN AND METHODS 
Study population 
The study population was men and women aged 30–64 years, who participated in the 
9-year follow-up study, D.E.S.I.R. Participants were recruited from volunteers offered 
periodic health examinations free of charge by the French Social Security, in 10 health 
examinations centres in western France. All subjects signed an informed consent and the 
protocol was approved by an ethics committee. 
 Incident cases of diabetes were identified by treatment for diabetes or a fasting 
plasma glucose ≥ 7.0 mmol/l, at one of the three-yearly examinations, after exclusion of 
individuals with diabetes at baseline and those with unknown diabetic status at the 9-year 
examination; the 1863 men and 1954 women who had glucose, BMI and waist 
circumference available at baseline were studied. in
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Measures 
Two measures of blood pressure, using a mercury sphygmomanometer, and of heart rate 
were taken in a supine position after 5 minutes rest; mean values were used. Weight and 
height were measured in lightly clad participants, and BMI calculated. The waist 
circumference, the smallest circumference between the lower ribs and the iliac crests, was 
also measured. 
 The examining physician noted the family history of diabetes and menopausal 
status in a clinical questionnaire; treatment for diabetes, hypertension and lipids were 
recorded. Hypertension was defined by systolic/diastolic blood pressures of at least 
140/90 mmHg or being on antihypertensive medication. Smoking habits, alcohol 
consumption (glasses per day of wine, beer, cider, spirits) and degree of physical activity 
(at home, at work and sport) were assessed using a self-administered questionnaire. 
 All biochemical measurements were from one of four health-centre laboratories 
located in France at Blois, Chartres, La Riche or Orléans. Fasting plasma glucose, 
measured by the glucose-oxidase method, was applied to fluoro-oxalated plasma using a 
Technicon RA100 (Bayer Diagnostics, Puteaux, France) or a Specific or a Delta device 
(Konelab, Evry, France). Total cholesterol, HDL-cholesterol, triglycerides, alanine 
aminotransferase (ALT), γ-glutamyltransferase (GGT), and creatinine were assayed by 
DAX 24 (Bayer Diagnostics, Puteaux, France) or KONE (Evry, France). Insulin was 
quantified by micro particle enzyme immunoassay with an automated analyzer IMX 
(Abbott, Rungis, France). White cell counts were determined by a Technicon H* or a 
Technicon H3RTX (Bayer Diagnostics, Puteaux, France) or a JT2 (Beckman/Coulter, 
Roissy, France) or an Argos (ABX, Montpellier, France). The inter-laboratory variability 
was assessed monthly on normal and pathological values for each biologic variable. 
 Single nucleotide polymorphism (SNP) genotyping was performed with the 
SNPlex™ Technology (Applied Biosystems, Foster City, CA) based on the Oligonucleotide 
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Ligation Assay (OLA) combined with multiplex PCR target amplification 
(http://www.appliedbiosystems.com) (14).  
 
Statistical methods 
Statistical analysis used SAS Version 9.1 (SAS Institute Inc. Cary, NC USA). Alcohol 
intake, BMI, fasting glucose, insulin, ALT, GGT, triglycerides and white blood cell count 
were log-transformed because of their skewed distributions. 
 Characteristics of men and women with and without incident diabetes are shown by 
means (SDs) or numbers (percentages) and compared by t- or χ²-tests, or by linear 
regression for the polymorphisms with additive models. The logistic model was used to 
test for interactions with sex and P-values are reported; significant interactions (P < 0.01) 
provided the rational for sex-specific models. 
The linearity of continuous parameters in logistic analyses was studied by adding a 
squared term and comparing nested models by likelihood ratio tests; all variables were 
linearly related with the logit of diabetes incidence excepting fasting glucose (log-
transformed); in the models, glucose (log) was centred by subtracting its mean, and its 
square was systematically included. 
Parsimonious logistic regression models were selected using forwards, backwards 
as well BEST model selection criteria using all parameters; the Hosmer-Lemeshow 
goodness-of-fit test was the principal criteria for selection of a model. Interactions with sex 
were tested. The area under the receiver operating characteristic sensitivity-specificity 
curve (AROC) quantified the discrimination between diabetic and non-diabetic participants. 
Bootstrap sampling was used to validate the choice of variables in the models, with 1000 
samples of the same sizes as the study populations. The choice of variables was also 
validated in the Cox model. 
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To derive a simple clinical score from the clinical equations, we used the beta 
coefficients from the logistic regression analysis; for waist circumference four groups were 
defined, linearly, from the approximate sex-specific quartiles. The score was validated in 
two French cohorts, E3N and SU.VI.MAX (15,16) (On-line figure 1). The first study 
identified incident diabetes by self-questionnaire or treatment reimbursement, the second 
by fasting glucose or treatment. 
Four polymorphisms were chosen for study (Glucokinase: GCK-30 G/A rs1799884, 
Interleukine 6: IL6-174 G/C rs1800795, Kir6.2: KCNJ11 E23K rs5219 and TCF7L2 
rs7903146) following previous analyses in this population (14). Additive models 
discriminated best between diabetic and non-didabetic people. For the two polymorphisms 
found to be the most related with incident diabetes (IL6, TCF7L2), the number of 
deleterious alleles (as a continuous variable) was calculated, and added as a variable to 
the (clinical + biological) equations chosen above. As this analysis aimed to determine 
those who should be screened for diabetes, we have analysed all individuals, and have 
not excluded those born outside of mainland France. This analysis was on a smaller 
population (1655 men, 1740 women) where these two polymorphisms were available. 
We compared our clinical risk score with the FINDRISC score (3) using the AROC-
statistic; FINDRISC includes age, BMI, waist circumference, anti-hypertensive medication, 
physical activity, previously known high glucose and daily consumption of vegetables, 
fruits or berries; we were not able to include latter two items. Our (clinical + biological) 
equation was compared with the Stern equation, including age, sex, fasting glucose, 
systolic blood pressure, HDL-cholesterol, BMI, diabetes in the family; we did not include 
the factor for coding Mexican Americans (9). 
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RESULTS 
In the D.E.S.I.R. population, 140 men and 63 women had incident diabetes 
 
Clinical predictors of incident diabetes 
All of the clinical variables showed similar relations with incident diabetes in both men and 
women with the exception of diabetes in the family: noted for 43% of women with incident 
diabetes, 19% in those without; for men 20% and 18% respectively (P sex-
interaction=0.003) (Table 1).  
 The first most predictive variable was waist circumference, closely followed by BMI, 
in both genders. The selected model in men included waist circumference, smoking and 
hypertension; for women, waist circumference, diabetes in the family, and hypertension 
(Table 2). These models showed a good fit (Hosmer-Lemeshow P-values: 0.7; 0.6, men; 
women respectively) and discriminated well the diabetic and non-diabetic populations 
(AROC 0.733; 0.839). In the bootstrap samples these were the most frequently chosen 
models. These variables were also chosen by the Cox modeling. 
 
Clinical risk score 
From the above equations, clinical risk scores were derived (Table 3). These scores 
showed a good fit (Hosmer-Lemeshow P-values: 0.8; 0.9 men women respectively) and 
the discrimination was similar to the more exact equation with continuous values of waist 
circumference.  
 The ROC curves for the clinical equation and for the simplified clinical score are 
shown for men and women (Fig. 1A); the D.E.S.I.R. scores with three variables had AROC 
values slightly higher than for the five-variable FINDRISC score. The score predicted 
diabetes in the two French cohorts, with AROCS similar to those from D.E.S.I.R. (On-line 
Figure). 
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Biologic predictors of incident diabetes 
Fasting glucose was by far the factor the most predictive of incident diabetes with a no 
difference in its effect between men and women (P interaction = 0.1) (Table 1). Predictive 
factors differing between genders were triglycerides and HDL-cholesterol: both had a 
slightly stronger relation in women (P sex-interaction = 0.006, 0.008 respectively).  
 
Clinical+Biological predictors of incident diabetes 
Fasting glucose (including its squared term) was the most predictive of all factors. After 
adjustment for fasting glucose, waist circumference was more predictive than BMI in men, 
but BMI was more predictive than waist in women (Table 2). In men, the predicting 
equation included fasting glucose, smoking status, waist circumference and GGT; for 
women, fasting glucose, BMI, diabetes in the family and triglycerides. The same variables 
were chosen by Cox modelling with five predictive variables. 
 Our (clinical + biological) equation was simpler than the Stern equation with only 
four variables, and discriminated similarly, incident diabetic individuals (Fig. 1B).  
 
Genetic polymorphisms as predictors of incident diabetes 
None of the four polymorphisms was significantly related with incident diabetes in either 
men or women, using either the three genotypes or recessive, dominant or additive 
models of inheritance (On-line Table). There was no interaction with sex, and combining 
men and women, TCF7L2 and IL6 were significantly related with incident diabetes using 
additive models (P < 0.01, 0.03 respectively). In comparison to individuals with no 
deleterious alleles, those with four deleterious alleles had an odds ratio of incident 
diabetes of 3.60 (1.09-11.9) in men and 3.22 (0.62-16.5) in women. The number of 
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deleterious alleles was associated with incident diabetes, in both men and women 
(P < 0.008; 0.03 respectively) (Table 1). 
 Including the total number of deleterious alleles in the above determined 
(clinical + biological) equations, they showed an adequate fit but changed little the AROC  
(Table 2).  
 
DISCUSSION 
Both the clinical and the (clinical+biological) equations are able to predict diabetes 
incidence over a 9-year follow-up, with different variables in the equations for men and 
women.  Age was not selected in any of the equations, but the effect of ageing would pass 
by other parameters such as adiposity, hypertension, glucose levels. Age was included in 
the equations of many (3,5,8-10) but not all of the other published studies of risk equations 
(7). Polymorphisms added little to these scores. As expected, the equations derived on our 
population performed slightly better than those derived in other populations. The clinical 
score performed well on two other French cohorts.  
Our diabetes risk score based on clinical data, has the advantage that it is simple, 
and requires only three parameters. Given a larger population and a higher incidence of 
diabetes, other parameters might have been included in the equations, but the 
discrimination and model fit may not be greatly improved. 
 BMI and waist circumference had similarly predictive values in both men and 
women; once one was included, the other no longer entered the model. Similar comments 
can be made for GGT and ALT. 
 In contrast to other scores, we have studied men and women separately and found 
that the predictive equations differ. In both sexes, waist circumference was the clinical 
factor the most related with incident diabetes, then in men smoking, which was more 
common in men than women; diabetes in the family was a predictive factor only in the 
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women. Hypertension was predictive of diabetes in both sexes, a factor often present 
before diabetes (17). Smoking is recognised as a risk factor for diabetes, with a higher risk 
for the heavy smokers in comparison to the lighter and former smokers (18). Our 
observation that more diabetic women than men have diabetes in the family, is probably 
due to women being more aware of their family diabetes. In the multivariate equations 
physical activity was not predictive – this could be because of its negative correlation with 
waist circumference and hypertension and perhaps because our questions on self-
reported physical activity were not sufficiently precise, in comparison to other data such as 
waist circumference and hypertension. Other studies have indeed included physical 
activity in their multivariate equations (3,7,8). 
 The overriding biological factor predictive of diabetes was the baseline glucose 
level. In the (clinical+biological) equation in men, the GGT also entered the equation, in 
women the triglycerides concentration. We have already shown that GGT is predictive of 
incident diabetes in this cohort, for both genders (19), and others have shown that 
triglycerides are predictive (5,10). 
 The polymorphisms studied provided little towards predicting diabetes: for the 1655 
men and 1740 women with these data available, the Hosmer-Lemeshow tests showed a 
poorer fit for men when the genetic data was included, but identical AROCs. Of note, in 
women, the coefficient for the parameter: diabetes in the family, was only reduced from 
0.80 to 0.75 when genetic parameters were included, indicating there are probably other 
genetic factors involved. A large panel of SNPs may be needed be to out-perform even 
simple clinical parameters.  
 One of the limitations is that we have not been able to include the 2-hour glucose 
concentration in our definition of diabetes: in France screening of diabetes with fasting 
glucose is common, so our score is appropriate in the local situation. A further limitation is 
that score is only for people between 30 and 65 years 
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The simplest clinical parameter for identifying those at risk of diabetes is adiposity – 
and taken alone, either waist circumference or BMI did equally well in predicting later 
diabetes during the nine year follow up. The addition of hypertension, and smoking in men, 
triglycerides in women provides a clinical score which discriminates well. 
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Figure Legends 
 
Figure 1—Receiver Operating Characteristic (ROC) curves and the AROC 
statistics in men and women for A. the D.E.S.I.R. French clinical equation, the 
French clinical risk score and the FINDRISC clinical score (3); B. the D.E.S.I.R 
(clinical+biological). French risk equation and the Stern risk equation (9).  
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Table 1—Clinical and biological characteristics [mean(SD) or number (%)] at baseline of men and women with and without incident diabetes 
during the 9 years of the D.E.S.I.R. study.  
 
 Men Women 
 Diabetes No diabetes Diabetes No diabetes 
 n=140 n=1723 P* n=63 n=1891 P* 
P for 
variable 
P interaction 
with sex 
Age (years) 50 (9) 47 (10) 0.0001 52 (8) 47 (10) 0.0005 0.0001† 0.6 
Diabetes in the family  28 (20%) 312 (18%) 0.6 27 (43%) 368 (19%) 0.0001 ‡ 0.003 
         
Current smoker 52 (37%) 418 (24%) 0.0009 10 (16%) 249 (13%) 0.5 0.001† 0.3 
Alcohol intake (g/day) § 34 (32) 23 (22) 0.005 8 (11) 7 (11) 0.5 0.006† 0.2 
         
Physical activity          
Little 43 (31%) 422 (24%)  22 (35%) 465 (25%)    
Moderate 72 (51%) 911 (53%) 0.07 33 (52%) 1036 (55%) 0.04 0.03† 0.7 
Intensive 25 (18%) 388 (23%)  8 (13%) 386 (20%)    
         
Waist circumference (cm) 96 (10) 89 (9) 0.0001 90 (12) 76 (10) 0.0001 0.0001† 0.3 
BMI (kg/m²) § 27.5 (4.0) 25.1 (3.0) 0.0001 29.2 (5.1) 23.7 (3.8) 0.0001 0.0001† 0.3 
         
Menopause    30 (48%) 718 (38%) 0.1   
Large baby, birth weight ≥ 4 kg    16 (27%) 284 (15%) 0.02   
         
Hypertension║ 87 (62%) 678 (39%) 0.0001 39 (62%) 527 (28%) 0.0001 0.0001 0.1 
Heart rate (min) 68 (10) 66 (10) 0.007 71 (11) 68 (9) 0.02 0.0005† 0.7 
Treatment for lipids 20 (14%) 126 (7%) 0.004 9 (14%) 129 (7%) 0.03 0.0003† 0.9 
         
Fasting glucose (mmol/l) § 6.05 (0.55) 5.39 (0.49) 0.0001 5.96 (0.58) 5.11 (0.46) 0.0001 0.0001† 0.1 
GGT (IU/l) § 64.3 (67.2) 39.5 (38.3) 0.0001 36.4 (33.6) 21.7 (21.2) 0.0001 0.0001† 0.4 
ALT (UI/l) § 41.7 (28.3) 30.3 (18.1) 0.0001 28.9 (22.2) 20.1 (13.8) 0.0001 0.0001† 0.4 
Triglycerides (mmol/l) § 1.79 (1.45) 1.26 (0.80) 0.0001 1.50 (0.78) 0.93 (0.50) 0.0001 ‡ 0.006 
HDL-cholesterol (mmol/l) 1.41 (0.37) 1.50 (0.38) 0.01 1.53 (0.34) 1.80 (0.42) 0.0001 ‡ 0.008 
Total-cholesterol (mmol/l) 6.06 (1.05) 5.82 (0.97) 0.009 5.94 (1.04) 5.61 (0.96) 0.02 0.0001† 0.6 
Creatinine (µmol/l) 91.0 (13.9) 89.1 (11.1) 0.06 77.1 (10.7) 74.1 (10.0) 0.02 0.006† 0.4 
White Blood Cell count (109/l) § 6.9 (2.1) 6.4 (1.7) 0.002 7.3 (4.0) 6.2 (1.6) 0.0002 0.0001† 0.2 
         
 n=135 n=1617  n=61 n=1782    
Number of TCF7L2, IL6  
                         deleterious alleles 2.0 1.8 0.008 2.2 1.8 0.03 0.0007 0.7 
 
* P-value comparing means and percentages, by t- and χ² tests 
† P-value for variable in logistic model with only variable and sex, as interaction not significant 
‡ P-value for variable not given, as the interaction is significant 
§ log-transformation because of a non-symmetric distributions 
║ hypertension: systolic / diastolic blood pressures > 140 / 90 mmHg or medication for hypertension 
in
se
rm
-0
03
01
91
5,
 v
er
sio
n 
1 
- 1
8 
Au
g 
20
08
7/21/2008  Page 19/20 
Table 2—Beta coefficients for the clinical, (clinical+biological), (clinical+biological+genetic) equations. The D.E.S.I.R. Study  
 
Men 
Variable Clinical Equation Clinical + Biological Equation Clinical + Biological + Genetic Equation 
 140 diabetic men, n=1860 140 diabetic men, n=1860 128 diabetic men, n=1655 
 beta P beta P beta P 
Intercept -10.45  -10.53  10.91  
Current smoker 0.72 0.0002 0.88 0.0001 0.94 0.0001 
Waist circumference (cm) 0.081 0.0001 0.060 0.0001 0.060 0.0001 
Hypertension * 0.50 0.01     
Fasting glucose (mmol/l) †   10.15 0.0001 10.17 0.0001 
Fasting glucose² †   24.16 0.002 22.42 0.007 
GGT (IU/l) †   0.39 0.01 0.42 0.007 
Number of TCF7L2, IL6  deleterious 
                                         alleles     0.14 0.2 
       
AROC-statistic 0.733 0.850 0.851 
Hosmer-Lemeshow fit test P = 0.7 P  = 0.8 P  = 0.1 
* glucose and GGT were log-transformed 
Women 
 Clinical Equation Clinical + Biological Equation Clinical + Biological + Genetic Equation 
 63 diabetic women n=1954 63 diabetic women n=1954 58 diabetic women, n=1740 
 beta P beta P beta P 
Intercept -11.81  -18.91  -20.43  
Diabetes in the family 1.09 0.0001 0.80 0.01 0.75 0.02 
Waist circumference (cm) 0.095 0.0001     
BMI (kg/m²) †   4.38 0.0001 4.69 0.0001 
Hypertension * 0.64 0.03     
Fasting glucose (mmol/l) †   9.66 0.001 9.35 0.001 
Fasting glucose² †   23.89 0.06 22.39 0.08 
Triglycerides (mmol/l) †   0.95 0.003 0.86 0.01 
Number of TCF7L2, IL6  deleterious 
                                         alleles   
  0.36 0.04 
       
AROC-statistic 0.839 0.917 0.912 
Hosmer-Lemeshow fit test P  = 0.6 P  = 0.9 P =0.8 
*  hypertension: systolic / diastolic blood pressures > 140 / 90 mmHg or medication for hypertension 
† fasting glucose, GGT, BMI and triglycerides were log-transformed 
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Table 3— A clinical diabetes risk score of 5 confers a more than 30% chance of diabetes in the following 9 years,The D.E.S.I.R. 
Study 
 
Men    Women   
  Scores to sum    Scores to sum 
Waist circumference  < 80 cm 0  Waist circumference (cm) < 70 cm 0 
 80-89 cm 1   70-79 cm 1 
 90-99 cm 2   80-89 cm 2 
 ≥ 100 cm 3   ≥ 90 cm 3 
Current Smoker - yes  1  Diabetes in the family - yes  1 
Hypertension* - yes  1  Hypertension - yes  1 
AROC-statistic 0.713  AROC-statistic 0.827 
Hosmer-Lemeshow fit test P  = 0.8  Hosmer-Lemeshow fit test P  = 0.9 
*  hypertension: systolic / diastolic blood pressures > 140 / 90 mmHg or medication for hypertension 
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